The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Hepatotoxicity of Tyrosine Kinase Inhibitors: Clinical and Regulatory Perspectives
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Summary of product characteristics
(2013) · Pharmaceutical Medicine · doi:10.1093/med/9780199609147.003.0027 · Cited by 1,905
Tyrosine Kinases as Targets for Cancer Therapy
Krause, D. S., & Van Etten, R. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra044389 · Cited by 1,387
HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin
study, F. T. D., Daly, A. K., International SAE Consortium, Donaldson, P. T., Bhatnagar, P., Shen, Y., Pe'er, I., Floratos, A., Daly, M. J., Goldstein, D. B., et al. (2009) · Nature Genetics · doi:10.1038/ng.379 · Cited by 944
ANDRADE, R., LUCENA, M., FERNANDEZ, M., PELAEZ, G., PACHKORIA, K., GARCIARUIZ, E., GARCIAMUNOZ, B., GONZALEZGRANDE, R., PIZARRO, A., & DURAN, J. (2005) · Gastroenterology · doi:10.1016/j.gastro.2005.05.006 · Cited by 856
Phase II Trial of Sorafenib in Advanced Thyroid Cancer
Gupta-Abramson, V., Troxel, A. B., Nellore, A., Puttaswamy, K., Redlinger, M., Ransone, K., Mandel, S. J., Flaherty, K. T., Loevner, L. A., O'Dwyer, P. J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.3279 · Cited by 680
Outcome and prognostic markers in severe drug‐induced liver disease†
Björnsson, E., & Olsson, R. (2005) · Hepatology · doi:10.1002/hep.20800 · Cited by 524
Goodman, V. L., Rock, E. P., Dagher, R., Ramchandani, R. P., Abraham, S., Gobburu, J. V. S., Booth, B. P., Verbois, S. L., Morse, D. E., Liang, C. Y., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2328 · Cited by 501
Kinetics and metabolism of paracetamol and phenacetin.
Prescott, L. (1980) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1980.tb01812.x · Cited by 454
Current Concepts of Mechanisms in Drug-Induced Hepatotoxicity
Russmann, S., Kullak-Ublick, G., & Grattagliano, I. (2009) · Current Medicinal Chemistry · doi:10.2174/092986709788803097 · Cited by 412
Mechanisms of Cardiac Dysfunction Associated With Tyrosine Kinase Inhibitor Cancer Therapeutics
Chen, M. H., Kerkelä, R., & Force, T. (2008) · Circulation · doi:10.1161/circulationaha.108.776831 · Cited by 379
Risk Factors for Idiosyncratic Drug-Induced Liver Injury
Chalasani, N., & Björnsson, E. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.04.001 · Cited by 347 · cited 1×
“of autoimmunity (ticrynafen), female gender (virtually all hepatotoxic drugs) and general drug hypersensitivity [10, 21].”
BackgroundCourt, M. H., Duan, S. X., von Moltke, L. L., Greenblatt, D. J., Patten, C. J., Miners, J. O., & Mackenzie, P. I. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29222-3 · Cited by 301
Central role of mitochondria in drug-induced liver injury
Pessayre, D., Fromenty, B., Berson, A., Robin, M.-A., Lettéron, P., Moreau, R., & Mansouri, A. (2012) · Drug Metabolism Reviews · doi:10.3109/03602532.2011.604086 · Cited by 277
Mechanisms of drug-induced liver injury: from bedside to bench
Tujios, S., & Fontana, R. J. (2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2011.22 · Cited by 277
Spraggs, C. F., Budde, L. R., Briley, L. P., Bing, N., Cox, C. J., King, K. S., Whittaker, J. C., Mooser, V. E., Preston, A. J., Stein, S. H., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.3197 · Cited by 275
Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib
Haouala, A., Widmer, N., Duchosal, M. A., Montemurro, M., Buclin, T., & Decosterd, L. A. (2011) · Blood · doi:10.1182/blood-2010-07-294330 · Cited by 268
Acetaminophen bioactivation by human cytochrome P450 enzymes and animal microsomes
Laine, J. E., Auriola, S., Pasanen, M., & Juvonen, R. O. (2009) · Xenobiotica · doi:10.1080/00498250802512830 · Cited by 262
Nakagawa, H., Maeda, S., Hikiba, Y., Ohmae, T., Shibata, W., Yanai, A., Sakamoto, K., Ogura, K., Noguchi, T., Karin, M., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.07.006 · Cited by 250
Non-steroidal anti-inflammatory drugs: What is the actual risk of liver damage?
Bessone, F. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i45.5651 · Cited by 248
Gonzalez, F. J. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.012492 · Cited by 213
Eder, J. P., Shapiro, G. I., Appleman, L. J., Zhu, A. X., Miles, D., Keer, H., Cancilla, B., Chu, F., Hitchcock-Bryan, S., Sherman, L., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0574 · Cited by 197
Reuben, A. (2004) · Hepatology · doi:10.1002/hep.20081 · Cited by 190
Troglitazone-induced liver failure: a case study
Graham, D. J., Green, L., Senior, J. R., & Nourjah, P. (2003) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01529-2 · Cited by 186
Can Pharmacogenetics Help Rescue Drugs Withdrawn from the Market?
Shah, R. R. (2006) · Pharmacogenomics · doi:10.2217/14622416.7.6.889 · Cited by 179
Self-citationShah, R. R., Morganroth, J., & Shah, D. R. (2013) · Drug Safety · doi:10.1007/s40264-013-0047-5 · Cited by 172
Self-citationRole of Reactive Metabolites in Drug-Induced Hepatotoxicity
Srivastava, A., Maggs, J. L., Antoine, D. J., Williams, D. P., Smith, D. A., & Park, B. K. (2009) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-00663-0_7 · Cited by 167
The Price We Pay for Progress: A Meta-Analysis of Harms of Newly Approved Anticancer Drugs
Niraula, S., Seruga, B., Ocana, A., Shao, T., Goldstein, R., Tannock, I. F., & Amir, E. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.3824 · Cited by 167
Pharmacogenetics of drug‐induced liver injury†
Russmann, S., Jetter, A., & Kullak-Ublick, G. A. (2010) · Hepatology · doi:10.1002/hep.23720 · Cited by 154
Tyrosine Kinase Inhibitors: Their On-Target Toxicities as Potential Indicators of Efficacy
Shah, D. R., Shah, R. R., & Morganroth, J. (2013) · Drug Safety · doi:10.1007/s40264-013-0050-x · Cited by 150
Self-citationMutlib, A. E., Goosen, T. C., Bauman, J. N., Williams, J. A., Kulkarni, S., & Kostrubsky, S. E. (2006) · Chemical Research in Toxicology · doi:10.1021/tx050317i · Cited by 149
Liver Enzyme Monitoring in Patients Treated With Troglitazone
Graham, D. J. (2001) · JAMA · doi:10.1001/jama.286.7.831 · Cited by 136
Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism
Xu, C., Reck, B. H., Xue, Z., Huang, L., Baker-Neblett, K. L., Chen, M., Chen, E. P., Ellens, H. M., Mooser, V., Cardon, L. R., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605653 · Cited by 128
Ticrynafen-Associated Hepatic Injury: Analysis of 340 Cases
Zimmerman, H. J., Lewis, J. H., Ishak, K. G., & Maddrey, W. C. (1984) · Hepatology · doi:10.1002/hep.1840040223 · Cited by 126
Signal Transduction Pathways Involved in Drug-Induced Liver Injury
Han, D., Shinohara, M., Ybanez, M. D., Saberi, B., & Kaplowitz, N. (2009) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-00663-0_10 · Cited by 121
Šeruga, B., Sterling, L., Wang, L. E., & Tannock, I. F. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.9624 · Cited by 112
The Pathology of Drug-Induced Liver Injury
Kleiner, D. (2009) · Seminars in Liver Disease · doi:10.1055/s-0029-1240005 · Cited by 108
CYP3A Phenotyping Approach to Predict Systemic Exposure to EGFR Tyrosine Kinase Inhibitors
Li, J., Karlsson, M. O., Brahmer, J. R., Spitz, A. N., Zhao, M., Hidalgo, M. M., & Baker, S. D. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj466 · Cited by 108
Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: A meta-analysis
Teo, Y. L., Ho, H. K., & Chan, A. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.09.004 · Cited by 98
Drug-Induced Liver Injury: Insights from Genetic Studies
Andrade, R. J., Robles‐Díaz, M., Ulzurrun, E., & Lucena, M. I. (2009) · Pharmacogenomics · doi:10.2217/pgs.09.111 · Cited by 96
Vascular endothelial growth factor and hepatocyte regeneration in acetaminophen toxicity
Donahower, B., McCullough, S. S., Kurten, R. C., Lamps, L. W., Simpson, P. M., Hinson, J., & James, L. P. (2006) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00575.2005 · Cited by 84
Lim, A. Y., Segarra, I., Chakravarthi, S., Akram, S., & Judson, J. P. (2010) · BMC Pharmacology · doi:10.1186/1471-2210-10-14 · Cited by 82
Feng, B., Xu, J. J., Bi, Y.-A., Mireles, R., Davidson, R., Duignan, D. B., Campbell, S., Kostrubsky, V. E., Dunn, M. C., Smith, A. R., et al. (2009) · Toxicological Sciences · doi:10.1093/toxsci/kfp033 · Cited by 80
Role of immune reactions in drug-induced liver injury (DILI)
Ju, C., & Reilly, T. (2012) · Drug Metabolism Reviews · doi:10.3109/03602532.2011.645579 · Cited by 77
Imatinib-induced fatal acute liver failure
Ridruejo, E., Cacchione, R., Villamil, A. G., Marciano, S., Gadano, A. C., & Mandó, O. G. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i48.6608 · Cited by 76
Imatinib mesylate as a cause of acute liver failure
Cross, T., Bagot, C. N., Portmann, B., Wendon, J. A., & Gillett, D. (2006) · American Journal of Hematology · doi:10.1002/ajh.20486 · Cited by 75
Kostrubsky, S. E., Sinclair, J. F., Strom, S. C., et al. (2005) · Toxicological Sciences · doi:10.1093/toxsci/kfi211 · Cited by 74
Mechanisms and Outcomes of Drug- and Toxicant-Induced Liver Toxicity in Diabetes
Wang, T., Shankar, K., Ronis, M. J. J., & Mehendale, H. M. (2007) · Critical Reviews in Toxicology · doi:10.1080/10408440701215100 · Cited by 73
Oncogenic Targets, Magnitude of Benefit, and Market Pricing of Antineoplastic Drugs
Amir, E., Šeruga, B., Martínez‐López, J., Kwong, R. C., Pandiella, A., Tannock, I. F., & Ocaña, A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.2393 · Cited by 73
Ohyashiki, K., Kuriyama, Y., Nakajima, A., Tauchi, T., Ito, Y., Miyazawa, H., Kimura, Y., Serizawa, H., & Ebihara, Y. (2002) · Leukemia · doi:10.1038/sj.leu.2402702 · Cited by 72
Inhibition of paracetamol glucuronidation by tyrosine kinase inhibitors
Liu, Y., Ramı́rez, J., & Ratain, M. J. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.03911.x · Cited by 66
Histological features of acute hepatitis after imatinib mesylate treatment
James, C., Trouette, H., Marit, G., Cony‐Makhoul, P., & Mahon, F. (2003) · Leukemia · doi:10.1038/sj.leu.2402910 · Cited by 59
Fatal hepatic necrosis following imatinib mesylate therapy
Lin, N., Sarantopoulos, S., Stone, J. R., Galinsky, I. A., Stone, R. M., DeAngelo, D. J., & Soiffer, R. J. (2003) · Blood · doi:10.1182/blood-2003-07-2323 · Cited by 58
Imatinib mesylate-induced acute liver failure in a patient with gastrointestinal stromal tumors
Tonyalı, Ö., Çoşkun, U., Yıldız, R., Karakan, T., Demırcı, U., Akyürek, N., Beneklı, M., & Buyukberber, S. (2009) · Medical Oncology · doi:10.1007/s12032-009-9284-y · Cited by 57
Kijima, T., Shimizu, T., Nonen, S., Furukawa, M., Otani, Y., Minami, T., Takahashi, R., Hirata, H., Nagatomo, I., Takeda, Y., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.3368 · Cited by 51
Suzumura, T., Kimura, T., Kudoh, S., Umekawa, K., Nagata, M., Matsuura, K., Tanaka, H., Mitsuoka, S., Yoshimura, N., Kira, Y., et al. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-568 · Cited by 49
Kikuchi, S., Muroi, K., Takahashi, S., Kawano-Yamamoto, C., Takatoku, M., Miyazato, A., Nagai, T., Mori, M., Komatsu, N., & Ozawa, K. (2004) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190412331272721 · Cited by 45
Fatal Liver Failure in a Patient on Acetaminophen Treated with Sunitinib Malate and Levothyroxine
Weise, A. M., Liu, C. Y., & Shields, A. F. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1l528 · Cited by 45
Protein Tyrosine Phosphatase 1B (PTP1B) Deficiency Accelerates Hepatic Regeneration in Mice
Revuelta‐Cervantes, J., Mayoral, R., Miranda, S., González‐Rodríguez, Á., Fernández, M., Martín‐Sanz, P., & Valverde, Á. M. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2010.12.020 · Cited by 44
Interaction of innovative small molecule drugs used for cancer therapy with drug transporters
Mandery, K., Glaeser, H., & Fromm, M. F. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01618.x · Cited by 42
Side Effects Related to Cancer Treatment: CASE 1. Hepatitis Following Treatment With Gefitinib
Ho, C., Davis, J. E., Anderson, F., Bebb, G. D., & Murray, N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.6650 · Cited by 42
Early Imatinib Mesylate-Induced Hepatotoxicity in Chronic Myelogenous Leukaemia
Kong, J. H., Yoo, S.-H., Lee, K. E., Nam, S. H., Kwon, J. M., Lee, S. M., Chang, H. J., Choi, M. Y., Cho, M. S., Mun, Y., et al. (2007) · Acta Haematologica · doi:10.1159/000111092 · Cited by 40
Münster, P. N., Britten, C. D., Mita, M. M., Gelmon, K. A., Minton, S. E., Moulder, S. L., Slamon, D. J., Guo, F., Letrent, S. P., Denis, L., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1539 · Cited by 38
Successful Treatment With Erlotinib After Gefitinib-Related Severe Hepatotoxicity
Takeda, M., Okamoto, I., Fukuoka, M., & Nakagawa, K. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.5496 · Cited by 36
Fukui, T., Otani, S., Hataishi, R., Jiang, S., Nishii, Y., Igawa, S., Mitsufuji, H., Kubota, M., Katagiri, M., & Masuda, N. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1212-5 · Cited by 34
Sorafenib-Induced Severe Acute Hepatitis in a Stable Liver Transplant Recipient
Herden, U., Fischer, L., Schäfer, H., Nashan, B., von Baehr, V., & Sterneck, M. R. (2010) · Transplantation · doi:10.1097/tp.0b013e3181daac69 · Cited by 32
Takeda, M., Okamoto, I., Tsurutani, J., Oiso, N., Kawada, A., & Nakagawa, K. (2012) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hys042 · Cited by 32
Seki, N., Uematsu, K., Shibakuki, R., & Eguchi, K. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.7109 · Cited by 31
Sorafenib-Induced Liver Failure: A Case Report and Review of the Literature
Hootegem, A. V., Verslype, C., & Steenbergen, W. V. (2011) · Case Reports in Hepatology · doi:10.1155/2011/941395 · Cited by 30
Imatinib mesylate-induced acute hepatitis in a patient treated for gastrointestinal stromal tumour
Pariente, A. E., Etcharry, F., Calès, V., Laborde, Y., Ferrari, S., & Biour, M. (2006) · European Journal of Gastroenterology & Hepatology · doi:10.1097/01.meg.0000216941.42306.0e · Cited by 30
Acute Hepatitis in a Patient With Cirrhosis and Hepatocellular Carcinoma Treated With Sorafenib
Llanos, L., Bellot, P., Zapater, P., Pérez‐Mateo, M., & Such, J. M. (2008) · The American Journal of Gastroenterology · doi:10.1038/ajg.2008.41 · Cited by 28
Kunimasa, K., Yoshioka, H., Iwasaku, M., Nishiyama, A., Korogi, Y., Masuda, G., Takaiwa, T., & Ishida, T. (2012) · Internal Medicine · doi:10.2169/internalmedicine.51.6285 · Cited by 26
Ku, G. Y., Chopra, A., & Lopes, G. D. L., Jr. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2010.08.012 · Cited by 25
Erlotinib-induced acute hepatitis in a patient with pancreatic cancer.
Saif, M. W. (2008) · PubMed · Cited by 21
The adaptive response (drug tolerance) helps to prevent drug-induced liver injury.
Lewis, J. H. (2012) · Europe PMC (PubMed Central) · Cited by 17
Nilotinib in a Patient With Postnecrotic Liver Cirrhosis Related to Imatinib
Spataro, V. J. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.5359 · Cited by 15
Spriet-Pourra, C., Auriche, M., & Richmond Pjb Publications Ltd. (1994) · OpenGrey (Institut de l'Information Scientifique et Technique) · Cited by 11
Multiple Myeloma Emerging after Prolonged Gefitinib Treatment for Non-Small Cell Lung Carcinoma
Lim, S. Y., Ando, S., Nishiyama, K., & Padival, S. (2011) · Case Reports in Oncology · doi:10.1159/000327689 · Cited by 5
Cited by
Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy
Cannarile, M. A., Weisser, M., Jacob, W., Jegg, A.-M., Ries, C. H., & Rüttinger, D. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0257-y · Cited by 1,020
Shyam Sunder, S., Sharma, U. C., & Pokharel, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01469-6 · Cited by 508
Steegmann, J. L., Baccarani, M., Breccia, M., Casado, L. F., García-Gutiérrez, V, Hochhaus, A., Kim, D.-W., Kim, T. D., Khoury, H. J., Le Coutre, P., et al. (2016) · Leukemia · doi:10.1038/leu.2016.104 · Cited by 482
Leise, M. D., Poterucha, J. J., & Talwalkar, J. A. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.09.016 · Cited by 356
Stine, J. G., & Lewis, J. H. (2016) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2016.1127756 · Cited by 104
Metadata
- Authors
- Shah, R. R., Morganroth, J., & Shah, D. R.
- Venue
- Drug Safety
- Published
- 2013-04-26
- Volume
- 36
- Issue
- 7
- Pages
- 491-503
- ISSN
- 0114-5916 (ISSN-L)
- 1179-1942
- OpenAlex
- W2065902287
- Cited by
- 252
- References
- 77
- FWCI
- 17.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.